Diagnosis and treatment of Tropheryma whipplei infection in patients with inflammatory rheumatic disease: Data from the French Tw-IRD registry - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement Accéder directement au contenu
Article Dans Une Revue Journal of Infection Année : 2024

Diagnosis and treatment of Tropheryma whipplei infection in patients with inflammatory rheumatic disease: Data from the French Tw-IRD registry

1 Centre de référence des maladies auto-immunes systémiques rares d'Île-de-France / National Reference Center for Rare Systemic Autoimmune Diseases
2 UB - Université de Bordeaux
3 SERVICE DE RHUMATOLOGIE - Rhumatologie Bordeaux
4 Service de neuroradiologie, imagerie des urgences [CHU de Dijon]
5 Service de Rhumatologie
6 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
7 Hôpital Cochin [AP-HP]
8 ECaMO - [CRESS - U1153 / UMR_A 1125] - Clinical Epidemiology Applied to Osteoarticular Diseases | Épidémiologie clinique appliquée aux maladies rhumatismales et musculo-squelettiques
9 Service de Rhumatologie [CHU Lariboisière]
10 SAINBIOSE - Santé Ingénierie Biologie Saint-Etienne
11 Service de Rhumatologie [CHU Gabriel-Montpied]
12 PHERE (UMR_S_1152 / U1152) - Physiopathologie et Epidémiologie des Maladies Respiratoires
13 AP-HP - Hôpital Bichat - Claude Bernard [Paris]
14 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
15 Hôpital Louis Mourier - AP-HP [Colombes]
16 Hôpital Lariboisière-Fernand-Widal [APHP]
17 CHU Bordeaux
18 LYOS - Physiopathologie, diagnostic et traitements des maladies osseuses / Pathophysiology, Diagnosis & Treatments of Bone Diseases
19 UNH - Unité de Nutrition Humaine
20 Service de Rhumatologie [CHU Clermont-Ferrand]
21 CHU Toulouse - Centre Hospitalier Universitaire de Toulouse
22 IRSD - Institut de Recherche en Santé Digestive
23 Centre de Rhumatologie [CHU Toulouse]
24 ImmunoConcept - Immunology from Concept and Experiments to Translation
25 Service de Rhumatologie [CHU Pellegrin]
26 RESO - Centre National de Référence des Maladies Auto-Immunes Systémiques Rares de l'Est et du Sud-Ouest
27 Infinity - Institut Toulousain des Maladies Infectieuses et Inflammatoires
28 CIC 1436 - Centre d'investigation clinique de Toulouse
29 UT3 - Université Toulouse III - Paul Sabatier
Damien Caillet Portillo
Maëva Masson
Alexia Michaut
  • Fonction : Auteur
Justine Vix-Portet
  • Fonction : Auteur
Vincent Germain
  • Fonction : Auteur
Laurent Arnaud
  • Fonction : Auteur

Résumé

Tropheryma whipplei infection can manifest as inflammatory joint symptoms, which can lead to misdiagnosis of inflammatory rheumatic disease and the use of disease -modifying antirheumatic drugs. We investigated the impact of diagnosis and treatment of Tropheryma whipplei infection in patients with inflammatory rheumatic disease. Methods: We initiated a registry including patients with disease -modifying antirheumatic drugs -treated inflammatory rheumatic disease who were subsequently diagnosed with Tropheryma whipplei infection. We collected clinical, biological, treatment data of the inflammatory rheumatic disease, of Tropheryma whipplei infection, and impact of antibiotics on the evolution of inflammatory rheumatic disease. Results: Among 73 inflammatory rheumatic disease patients, disease-modifying antirheumatic drugs initiation triggered extra-articular manifestations in 27% and resulted in stabilisation (51%), worsening (34%), or improvement (15%) of inflammatory rheumatic disease. At the diagnosis of Tropheryma whipplei infection, all patients had rheumatological symptoms (mean age 58 years, median inflammatory rheumatic disease duration 79 months), 84% had extra-rheumatological manifestations, 93% had elevated C-reactive protein, and 86% had hypoalbuminemia. Treatment of Tropheryma whipplei infection consisted mainly of doxycycline plus hydroxychloroquine, leading to remission of Tropheryma whipplei infection in 79% of cases. Antibiotic treatment of Tropheryma whipplei infection was associated with remission of inflammatory rheumatic disease in 93% of cases and enabled disease-modifying antirheumatic drugs and glucocorticoid discontinuation in most cases. Conclusions: Tropheryma whipplei infection should be considered in inflammatory rheumatic disease patients with extra-articular manifestations, elevated C-reactive protein, and/or hypoalbuminemia before disease-modifying antirheumatic drugs initiation or in inflammatory rheumatic disease patients with an inadequate response to one or more disease-modifying antirheumatic drugs. Positive results of screening and diagnostic tests for Tropheryma whipplei infection involve antibiotic treatment, which is associated with complete recovery of Tropheryma whipplei infection and rapid remission of inflammatory rheumatic disease, allowing disease-modifying antirheumatic drugs and glucocorticoid discontinuation. (c) 2023 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association.
Fichier principal
Vignette du fichier
1-s2.0-S0163445323005960-main IRSD VENDREDI.pdf (526.63 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Licence : CC BY NC ND - Paternité - Pas d'utilisation commerciale - Pas de modification

Dates et versions

hal-04495049 , version 1 (08-03-2024)

Licence

Paternité - Pas d'utilisation commerciale - Pas de modification

Identifiants

Citer

Damien Caillet Portillo, Xavier Puéchal, Maëva Masson, Marie Kostine, Alexia Michaut, et al.. Diagnosis and treatment of Tropheryma whipplei infection in patients with inflammatory rheumatic disease: Data from the French Tw-IRD registry. Journal of Infection, 2024, 88 (2), pp.132-138. ⟨10.1016/j.jinf.2023.12.010⟩. ⟨hal-04495049⟩
51 Consultations
5 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More